| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BIOC Stock Overview
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample.
Biocept Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.42 |
| 52 Week High | US$4.97 |
| 52 Week Low | US$1.40 |
| Beta | 0.66 |
| 1 Month Change | -21.55% |
| 3 Month Change | -44.31% |
| 1 Year Change | -68.65% |
| 3 Year Change | -89.08% |
| 5 Year Change | -99.68% |
| Change since IPO | -99.98% |
Recent News & Updates
Shareholder Returns
| BIOC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.8% | 5.7% | 0.5% |
| 1Y | -68.7% | -21.4% | -11.5% |
Return vs Industry: BIOC underperformed the US Biotechs industry which returned -19.5% over the past year.
Return vs Market: BIOC underperformed the US Market which returned -8.1% over the past year.
Price Volatility
| BIOC volatility | |
|---|---|
| BIOC Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 12.4% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIOC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: BIOC's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 179 | Sam Riccitelli | https://biocept.com |
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer.
Biocept Fundamentals Summary
| BIOC fundamental statistics | |
|---|---|
| Market Cap | US$26.03m |
| Earnings (TTM) | -US$2.82m |
| Revenue (TTM) | US$61.25m |
0.4x
P/S Ratio-8.5x
P/E RatioIs BIOC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOC income statement (TTM) | |
|---|---|
| Revenue | US$61.25m |
| Cost of Revenue | US$37.76m |
| Gross Profit | US$23.49m |
| Other Expenses | US$26.31m |
| Earnings | -US$2.82m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 38.34% |
| Net Profit Margin | -4.61% |
| Debt/Equity Ratio | 0% |
How did BIOC perform over the long term?
See historical performance and comparisonValuation
Is Biocept undervalued compared to its fair value and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BIOC ($1.42) is trading below our estimate of fair value ($9.16)
Significantly Below Fair Value: BIOC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BIOC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: BIOC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIOC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIOC is good value based on its PB Ratio (0.6x) compared to the US Biotechs industry average (1.5x).
Future Growth
How is Biocept forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
1/6Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
20.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BIOC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BIOC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BIOC's revenue (9.3% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: BIOC's revenue (9.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BIOC's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Biocept performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
14.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIOC is currently unprofitable.
Growing Profit Margin: BIOC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BIOC is unprofitable, but has reduced losses over the past 5 years at a rate of 14.9% per year.
Accelerating Growth: Unable to compare BIOC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: BIOC has a negative Return on Equity (-7.53%), as it is currently unprofitable.
Financial Health
How is Biocept's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BIOC's short term assets ($45.7M) exceed its short term liabilities ($11.8M).
Long Term Liabilities: BIOC's short term assets ($45.7M) exceed its long term liabilities ($11.2M).
Debt to Equity History and Analysis
Debt Level: BIOC is debt free.
Reducing Debt: BIOC has no debt compared to 5 years ago when its debt to equity ratio was 407.7%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BIOC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BIOC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 5.3% per year.
Dividend
What is Biocept current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BIOC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BIOC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIOC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIOC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BIOC has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.3yrs
Average management tenure
CEO
Sam Riccitelli (62 yo)
0.25
Tenure
US$103,041
Compensation
Mr. Samuel D. Riccitelli, also known as Sam, serves as Independent Director at Biocept, Inc. since October 21, 2020 and Independent Chairman since July 2021. Mr. Riccitelli serves as Interim President and...
Leadership Team
Experienced Management: BIOC's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
Experienced Board: BIOC's board of directors are seasoned and experienced ( 11.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.1%.
Top Shareholders
Company Information
Biocept, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Biocept, Inc.
- Ticker: BIOC
- Exchange: NasdaqCM
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$26.032m
- Shares outstanding: 16.90m
- Website: https://biocept.com
Number of Employees
Location
- Biocept, Inc.
- 9955 Mesa Rim Road
- San Diego
- California
- 92121
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/18 00:00 |
| End of Day Share Price | 2022/05/18 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.